The haemophilia treatment landscape is fast evolving, with many new and innovative therapies in the final stages of development or being marketed in Europe. To help our members navigate these changes, the EHC has developed a publication, the New Product Review, issued twice a year with the latest therapeutic developments. The New Product Review Committee members support EHC staff in developing the content of this newsletter.
This committee is composed of:
Paul Batty
University College London, UK
Mariëtte Driessens
Dutch NMO
Radoslaw Kaczmarek
Polish NMO
Ilmar Kruis
Dutch NMO
David Lillicrap
Queen’s University, Canada
Mike Makris
Chair, EHC MAG, UK
Declan Noone
EHC President, Irish NMO
Brian O’Mahony
EHC MASAG member, Irish NMO
David Page
Canadian Haemophilia Society
Flora Peyvandi
EHC MAG, Italy
Suthesh Sivalaparatnam
Queen Mary University of London, UK
Uwe Schlenkrich
Germany
In addition to these volunteers, the New Product Review is also edited by some EHC MAG and MASAG members.
The work of this committee is supported by Laura Savini, EHC Communications and Public Policy Officer.
Jim is aged 66 and has Haemophilia A with a high titer inhibitor which he developed at age 14.
Maria Elisa Mancuso (MD, PhD) is a Haematologist and works as a Senior Haematology Consultant at the Center for Thrombosis and Haemorrhagic Diseases of IRCCS Humanitas Research Hospital in Rozzano, Milan, Italy. She is Adjunct Clinical Professor at Humanitas University. She obtained a post-degree in Clinical and Experimental Haematology and a PhD in Clinical Methodology. She is involved in clinical research and has published several original articles in peer-reviewed journals a The Lancet, Blood, Journal of Thrombosis and Haemostasis, Haematologica, Thrombosis and Haemostasis, British Journal of Haematology and Haemophilia. She is reviewer for several peer-reviewed journals and member of the Editorial Board of JTH. She is a member of several scientific societies (ISTH, WFH, ASH, EAHAD, SISET, AICE) and was a medical member of the Inhibitor Working Group of the European Hemophilia Consortium. She is co-chair of the ADVANCE Study Group. She has acted also as co-chair of the Scientific and Standardization Subcommittee of ISTH on FVIII, FIX and rare bleeding disorders. She has been involved as principal and co-investigator in several clinical trials, and she takes care of both children and adults with hemophilia and other congenital bleeding disorders with a specific scientific interest in novel therapies, prophylaxis, inhibitors, and chronic hepatitis C.
As a patient with factor II deficiency, the diagnostic and treatment of rare bleeding disorders is a matter dear to my heart. My motivation to participate in the work of the ERIN committee is to improve both diagnostic and treatment for patients with rare bleeding disorders across Europe.
Economist and financial expert by profession, executive coach and trainer by passion and haemophilia advocate by every drop of my blood through my son (who has severe haemophilia A with inhibitors). Bringing a good decade of practical experience from the corporate insurance world, laser focus, growth mindset and resilience from my own experience, offering you anything I can just do, in hope that together we can make life more fulfilled for those impacted by bleeding disorders.
Amy Owen-Wyard is a Registered Mental Health Nurse. With experience working with children, young people, their families and adults with severe and enduring mental health conditions. Amy was also involved in a service improvement to provide a holistic care approach for those in general hospitals to support both their mental and physical health, whilst sharing her expertise and knowledge in mental health with the wider multidisciplinary team.
